Medication Assisted Treatment (MAT)

To date, there is strong evidence to support the use of MAT (usually methadone, buprenorphine or naltrexone) in opioid addiction. Yet, there remains a stigma of “replacing one drug with another” and 25% of publicly funded treatment programs offer FDA approved MAT.

MAT:

• Decreases withdrawal in the early phases of recovery
• Decreases cravings
• Decreases risky activities associated with obtaining medications or drugs
• The POATS study found that approximately 61% of patients taking buprenorphine-naloxone as MAT with standard medical management remained abstinent from opioids at 3 ½ years.
